Schering Nitro-Dur Is One Target Of IG Medicaid Rebate Investigation
Executive Summary
Schering-Plough's Nitro-Dur (transdermal nitroglycerin) is one target of an investigation by the HHS Office of the Inspector General into the classification of brand name drugs for Medicaid
You may also be interested in...
Medicaid Best Price Reform: Dual-Eligible Move To Medicare May Be 1st Step
The effect of moving 60% of the prescriptions covered by Medicaid into Medicare is one issue being considered by the Medicare prescription drug conference committee as it determines how to handle "dual-eligibles.
Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count
A criminal investigation of Schering-Plough's marketing practices includes off-label promotion, the company disclosed May 30
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011